anti-CEACAM6 CAR T-cell therapy VHH antibody fragment (Helix BioPharma)

N/A

Report date: 2025/01/26 18:41:15

Base Information

Drug Nameanti-CEACAM6 CAR T-cell therapy VHH antibody fragment (Helix BioPharma)

Drug Alias Nameanti-CEACAM6 CAR T-cell therapy (National Research Council of Canada)

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 6 modulators

TargetsCarcinoembryonic antigen related cell adhesion molecule 6

Therapy Area/IndicationsSolid tumoursPancreatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanada

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNational Research Council Canada

China Registration ClassN/A

Develop Information

Active CompaniesHelix Biopharma Corp

Inactive CompaniesN/A

Active IndicationsSolid tumoursPancreatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A